April 29, 2024 06:59 AM EDTUpdated 08:33 AM
R&D

Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

Amber Tong

The top ex­per­i­men­tal drug stem­ming from John­son & John­son’s long-run­ning al­liance with Ad­dex Ther­a­peu­tics has failed a Phase 2 epilep­sy study, cast­ing a shad­ow over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times